Scientists See Signs of Progress in Alzheimer's Research With New Drugs and Therapies

For decades, medical research into Alzheimer’s disease faced significant hurdles, hindered by limited progress, groupthink, and systemic challenges within the scientific community. More than 7 million Americans live with Alzheimer's, the most common cause of dementia, which remains incurable and robs patients of their identity. However, recent developments suggest the field may be turning a corner.

According to reporting discussed by Vox senior correspondent Dylan Scott on the Today, Explained podcast, two Food and Drug Administration-approved drugs—lecanemab and donanemab—are now available to treat the disease directly. These treatments target amyloid plaque in the brain, a factor long associated with Alzheimer’s development. While the amyloid hypothesis was historically controversial due to slow progress in the field, clinical trials have shown these medications can clear amyloid plaque and slow cognitive decline for patients.

Beyond amyloid-targeting treatments, researchers are expanding their focus to include a broader range of biological mechanisms. Scientists are increasingly examining the role of tau proteins, chronic inflammation, and vascular health—such as the body's ability to pump blood—in the progression of Alzheimer’s. Early-stage clinical trials are currently evaluating treatments directed at tau proteins to check for safety while collecting preliminary data on their effectiveness.

Experts note that future care could resemble modern cancer treatment, utilizing a combination of therapies that target multiple mechanisms simultaneously to halt or eventually reverse disease progression. While reversing Alzheimer's symptoms remains out of reach for now, researchers hope a more robust suite of treatments will be available to patients within the next five to ten years.

Additionally, researchers are investigating whether widely used medications for other conditions might help prevent dementia down the road. GLP-1 receptor agonists, popular for weight loss, are drawing significant scientific interest due to potential links between vascular health and cognitive health. By helping individuals lose weight and lower blood pressure, these drugs could theoretically reduce the risk of vascular and heart problems that may contribute to cognitive decline. The Alzheimer's Association is backing this line of inquiry with a $100 million investment in research projects.

International developments have also captured the attention of the scientific community, including an experimental surgical procedure pioneered in China. The surgery involves creating a drain in a patient's brain intended to help clear out amyloid and tau proteins. While before-and-after videos of patients undergoing the procedure have generated widespread attention and skepticism alike, researchers in the United States and Europe are exploring the possibility of setting up independent studies to evaluate the findings. The surgeon who pioneered the technique has reportedly been detained by the Chinese government on insurance fraud charges, and authorities have moved to restrict the surgery outside of clinical trials.

Despite these complexities, scientists emphasize that the ultimate goal remains finding safe and effective ways to restore cognitive function and help patients reclaim their identities from a devastating condition.